Breast cancer
11 articles shown
Told It's 'Stage 2' Breast Cancer, but the Stage May Change After Surgery — Understanding Clinical vs. Pathologic Staging and Why Treatment Order Differs
Breast cancer staging estimated before surgery (clinical stage) can differ from the stage confirmed by pathology after surgery, and the sequence of surgery, chemotherapy, radiation, and hormone or targeted therapy varies by subtype such as hormone receptor and HER2 status.
When the Chest Still Hurts After a Mastectomy — How Surgical-Site Pain Eases and How to Help Your Shoulder and Arm Recover
Chest-wall pain after a mastectomy usually peaks in the first one to two weeks and dulls over the following weeks, while nerve-related tingling may last for months. Gentle, approved stretching helps prevent shoulder stiffness, and warning signs such as fever, discharge, or arm swelling should be reported promptly.
When Five Years of Anti-Hormone Therapy Feels Long: Side Effects and Tips for Getting Through
For hormone receptor-positive breast cancer, the long stretch of five to ten years of anti-hormone therapy is a burden. This calmly lays out the side effects of tamoxifen and aromatase inhibitors (hot flashes, joint pain, osteoporosis, blood clots, and more), ways to ease them in daily life, how to adjust medication with your doctor rather than stopping on your own, and tips for protecting your peace of mind.
If You Still Hope for a Child: What You Must Ask Before Starting Breast Cancer Treatment
This covers fertility preservation that young breast cancer patients should consider before treatment. It calmly lays out how chemotherapy affects the ovaries, methods such as egg, embryo, and ovarian tissue freezing, the realities of schedule and cost, and the importance of asking your medical team first before treatment begins.
HER2-Positive Breast Cancer: What Makes Targeted Therapy Different
HER2 is a protein that acts like a switch making cancer cells grow; when there is too much of it, it is HER2-positive breast cancer. Unlike ordinary chemotherapy that attacks indiscriminately, targeted therapy blocks only the HER2 signal, tends to have fewer side effects, and is usually used together with chemotherapy. Drugs such as trastuzumab have advanced, but heart function must be checked periodically.
What Is Triple-Negative Breast Cancer? A Step-by-Step Look at Why It Is Called a Tricky Cancer
Triple-negative breast cancer is a type in which both the hormone receptors and HER2 are negative, so hormone and HER2 targeted therapies do not work, which is why it is considered tricky. But as immunotherapy and new targeted drugs increase, the treatment options are widening — this article explains that step by step.
BRCA Genetic Testing — Should You Definitely Get It If You Have a Family History?
BRCA gene mutations raise the risk of breast and ovarian cancer but do not make the disease certain. If you have a family history such as onset at a young age, cancer in both breasts, breast and ovarian cancer together, or male breast cancer, it is good to get genetic counseling before testing. More important than the test itself are interpreting the result, the management that follows, and being mentally prepared.
Premenopausal Breast Cancer — Why Is an Ovarian Function Suppression Injection Recommended?
Hormone receptor-positive breast cancer grows by feeding on estrogen, so for premenopausal women, treatment that blocks the hormone supply with an ovarian function suppression injection is sometimes added. It is recommended especially when the risk of recurrence is high, and although it has side effects similar to menopause, they generally recover once the injections stop. Whether to undergo it is decided with the medical team, weighing both the risk level and your physical condition.
When They Say Triple-Negative Breast Cancer Is Tricky, What Does It Mean?
Triple-negative breast cancer is the type where all three markers - ER, PR, and HER2 - are negative, accounting for about ten to fifteen percent of cases. The core of why it is called tricky is having few targets to aim at, like anti-hormone or HER2 therapy - it does not mean there is no treatment. Options such as immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors for BRCA mutations are widening, and the course differs by tumor characteristics and stage even under the same label.
HER2-Positive Breast Cancer: Who Gets Targeted Therapy, and Why?
HER2-positive breast cancer overexpresses the HER2 protein and accounts for roughly one in five cases. Targeted drugs such as trastuzumab (Herceptin), pertuzumab, and T-DM1 attack HER2 directly to improve outcomes. Eligibility is set by biopsy (IHC 3+ or FISH-positive), and some of these drugs require heart-function monitoring.
Not Every Breast Cancer Means Chemo - When Chemotherapy Is Skipped
Breast cancer treatment depends on the subtype - hormone receptor-positive, HER2-positive, or triple-negative - and not every case calls for chemotherapy. When a tumor is hormone-positive and its genomic recurrence-risk score is low, many patients receive anti-hormone therapy alone without chemo, and even with lymph node involvement the decision hinges on the overall risk picture. The final call is made only after all test results are in, in conversation with your oncologist.